Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents

Cancer-associated thrombosis (CAT) brings additional costs to health expenditures and has a negative impact on oncological outcomes . Anticoagulation is the cornerstone of the treatment, but management of CAT remains complex . New risk scoring systems or biomarkers are needed to identify patients who are more likely to benefit from prophylaxis with low bleeding risk .

Leave a Reply